Linezolid + Vancomycin

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Methicillin-Resistant Staphylococcus Aureus (MRSA)

Conditions

Methicillin-Resistant Staphylococcus Aureus (MRSA), Hospital-Acquired Pneumonia

Trial Timeline

Nov 1, 2008 → Jun 1, 2013

NCT ID

NCT01561469

About Linezolid + Vancomycin

Linezolid + Vancomycin is a pre-clinical stage product being developed by Pfizer for Methicillin-Resistant Staphylococcus Aureus (MRSA). The current trial status is completed. This product is registered under clinical trial identifier NCT01561469. Target conditions include Methicillin-Resistant Staphylococcus Aureus (MRSA), Hospital-Acquired Pneumonia.

What happened to similar drugs?

1 of 2 similar drugs in Methicillin-Resistant Staphylococcus Aureus (MRSA) were approved

Approved (1) Terminated (0) Active (1)

✅Imipenem/cilastatinPfizerApproved

🔄Dalbavancin + Vancomycin + Oxacillin + Flucloxacillin + Cefadroxil + ClindamycinAbbViePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01561469	Pre-clinical	Completed	Nov 1, 2008	Jun 1, 2013	Methicillin-Resistant Staphylococcus Aureus (MRSA)
NCT00087490	Approved	Completed	Oct 1, 2004	Jul 1, 2007	Skin/Soft Tissue Infections
NCT00035425	Phase 3	Completed	Nov 1, 2001	Nov 1, 2002	Febrile Neutropenia

Competing Products

2 competing products in Methicillin-Resistant Staphylococcus Aureus (MRSA)

See all competitors

Product	Company	Stage	Hype Score
Dalbavancin + Vancomycin + Oxacillin + Flucloxacillin + Cefadroxil + Clindamycin	AbbVie	Phase 3	40
Imipenem/cilastatin	Pfizer	Approved	39